Pharmacy Times July 7, 2023
Expert Nikhil Palekar, MD, said that although the treatment is far from a cure, it is a vital first step toward other treatments for Alzheimer Disease.
In an interview with Pharmacy Times, Nikhil Palekar, MD, director of the Stony Brook Center of Excellence for Alzheimer Disease, director of the Stony Brook Division for Geriatric Psychiatry, and director of the Stony Brook Alzheimer Disease clinical trials program, discussed the FDA approval of lecanemab-irmb (Leqembi, Eisai). Although the treatment is not a cure and cannot reverse early Alzheimer disease, Palekar said it could give patients crucial more time to join other clinical trials investigating potential treatments.
Q: What did the pathway to this approval look like for lecanemab?
Nikhil Palekar, MD: Well...
Today's Sponsors
Today's Sponsor